Investment Thesis
Veracyte demonstrates exceptional profitability with 72.7% gross margins and 20.6% net margins in medical diagnostics, backed by a fortress balance sheet with zero debt and $263M cash. However, 174.9% net income growth and stagnant ROE (2.1%) and ROA (2.0%) raise sustainability questions and suggest inefficient capital deployment despite strong operational fundamentals.
Strengths
- Exceptional profitability margins (72.7% gross, 20.6% net) and strong FCF generation (23.2% margin)
- Zero debt with $263.1M cash and 9.31x current ratio providing substantial financial flexibility
- Revenue growth accelerating with 16% YoY increase and exceptional 174.9% net income growth YoY
- Medical laboratory services in recurring revenue healthcare sector with structural growth tailwinds
Risks
- Extreme 174.9% net income growth appears unsustainable and likely represents one-time improvement rather than normalized run-rate
- Dangerously low ROE (2.1%) and ROA (2.0%) indicate company is deploying $1.3B equity inefficiently despite profitability
- Excessive cash position (9.31x current ratio) suggests potential capital deployment inefficiency or strategic uncertainty
- Regulatory risks in healthcare diagnostics and potential competitive commoditization of testing services
Key Metrics to Watch
- Net income growth normalization - track whether 174.9% jump was one-time event or sustainable improvement
- ROE and ROA trends - critical to understand if company improves capital deployment efficiency
- Free cash flow to revenue conversion - monitor sustainability of 23.2% FCF margin
- Revenue growth rate - whether 16% growth is maintained or decelerates in coming quarters
Financial Metrics
Revenue
139.1M
Net Income
28.7M
EPS (Diluted)
$0.35
Free Cash Flow
32.3M
Total Assets
1.4B
Cash
263.1M
Profitability Ratios
Gross Margin
72.7%
Operating Margin
16.3%
Net Margin
20.6%
ROE
2.1%
ROA
2.0%
FCF Margin
23.2%
Balance Sheet & Liquidity
Current Ratio
9.31x
Quick Ratio
8.94x
Debt/Equity
0.00x
Debt/Assets
6.4%
Interest Coverage
195.22x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:56:44.709253 |
Data as of: 2026-03-31 |
Powered by Claude AI